Clinical trials
Metabolic Dysfunction-Associated Liver Disease clinical trials
Below are recruiting metabolic dysfunction-associated liver disease clinical trials, each written for real people, not researchers. We’re tracking 112 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT05945537RecruitingPhase 1
Testing INI-822 in healthy people and those with MASH
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
Camperdown, New South WalesAges 18–70 - NCT05648214RecruitingPhase 1/Phase 2
Testing a new liver medicine in people with fatty liver
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
Glendale, CaliforniaAges 18–75 - NCT05519475RecruitingPhase 2
Gene-silencing medicine trial for adults with MASH and liver scarring
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Chandler, ArizonaAges 18–75 - NCT04873258Recruiting
Test a non-invasive tool to screen for fat-related liver disease
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
London, LondonAges 18–80 - NCT07791043RecruitingPhase 2
Efimosfermin alfa for alcohol-related liver disease
This study tests an investigational medicine called efimosfermin alfa to see if it is safe and effective for people with liver damage caused by heavy drinking. The medicine is compared to a placebo (a dummy treatment).
Topeka, KansasAges 18–75 - NCT06215716RecruitingPhase 3
Efruxifermin for NASH/MASH with liver scarring
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
Birmingham, AlabamaAges 18–80 - NCT05870969Recruiting
Digital monitoring to catch liver cancer risk early
This study tests a digital (computer/phone-based) system to help track people with higher risk of liver cancer so cancers can be found earlier. It may help by guiding regular check-ins and making early diagnosis more efficient.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT07820644Recruiting
Liver cancer risk prediction in chronic liver disease
This study aims to predict the risk of developing liver cancer in people with chronic liver conditions such as hepatitis B or C, cirrhosis, or fatty liver disease. By participating, you may help researchers improve early detection and prevention strategies for liver cancer.
Shenzhen, GuangdongAges 18–75 - NCT07269041RecruitingPhase 1/Phase 2
Immune tolerance after liver transplant
This trial tests a way to help your body accept your liver transplant without needing lifelong anti-rejection drugs. It uses your living donor's stem cells to train your immune system to not attack the new liver.
Los Angeles, CaliforniaAges 18 years+ - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT06891365RecruitingPhase 1
Multiple doses of a new drug for fatty liver disease
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
HarrowAges 18–64 - NCT06453915RecruitingEarly Phase 1
Brain PET scan for inflammation in fatty liver disease
This study uses a special PET scan to look for inflammation in the brain related to fatty liver disease. It may help researchers understand how liver health affects brain function.
Sacramento, CaliforniaAges 18 years+
Hear when a new Metabolic Dysfunction-Associated Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metabolic dysfunction-associated liver disease?
- Yes. Clin2 currently lists 112 recruiting metabolic dysfunction-associated liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metabolic dysfunction-associated liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metabolic dysfunction-associated liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Metabolic Associated Fatty Liver Disease
- Metabolic Associated Steatotic Liver Disease
- Liver Dysfunction
- Alcohol-associated Liver Disease
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.